A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
| ClinicalTrials.gov Identifier |
| NCT05849480 |
| Institution Name |
| National Cancer Institute |
| Full Institution Address |
|
Bethesda Maryland 20892 United States |
| Institution Website |
| https://ccr.cancer.gov |
| Principal Investigator |
| Cecilia Monge |
| Principal Investigator Phone |
| (240) 858-3603 |
| Principal Investigator Email |
| cecilia.mongebonilla@nih.gov |
| Additional Principal Investigators |
|
Tim Greten (240) 760 6114 tim.greten@nih.gov |
| Study Coordinator |
| Donna Mabry Hrones |
| Study Coordinator Phone |
| (240) 858-3155 |
| Study Coordinator Email |
| donna.mabry@nih.gov |
| Study Overview |
| In this study we test the combination of two different immunotherapy drugs (anti-CD40 and anti-PD1) in combination with chemotherapy (capecitabine and oxaliplatin (CAPOX). This study is being offered to all patients who failed first-line treatment or refused first-line therapy. The study concept and preclinical data has been supported by the CCF. |
| Enrollment Information |
| 26 |
| Study Start Date |
| 20240327 |
| Study End Date |
| 20250331 |
| Study Purpose |
|
| Inclusion Criteria |
|
| Exclusion Criteria |
|
| Required Tests Prior to Study |
|
| Potential Side Effects |
|
| Financial Assistance Available |
| Yes |